Hennion & Walsh Asset Management, Inc. Intercept Pharmaceuticals, Inc. Transaction History

Hennion & Walsh Asset Management, Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 27, 2023	BUY	$9.99 - $18.71 $218,561 - $409,337	21,878 Added 89.53%	46,315 $858,000
Q2 2023 Aug 09, 2023	BUY	$9.17 - $19.29 $224,087 - $471,389	24,437 New	24,437 $270,000
Q3 2022 Nov 14, 2022	SELL	$12.21 - $19.7 $53,101 - $85,675	-4,349 Reduced 5.35%	76,984 $1.07 Million
Q2 2022 Jul 19, 2022	SELL	$11.23 - $19.59 $310,520 - $541,683	-27,651 Reduced 25.37%	81,333 $1.12 Million
Q1 2022 Apr 26, 2022	SELL	$13.37 - $17.79 $57,009 - $75,856	-4,264 Reduced 3.77%	108,984 $1.77 Million

Q4 2021 Feb 14, 2022	SELL	$14.28 - $19.53 $335,180 - $458,408	-23,472 Reduced 17.17%	113,248 $1.85 Million
Q3 2021 Nov 12, 2021	SELL	$12.99 - $20.47 $52,453 - $82,657	-4,038 Reduced 2.87%	136,720 $2.03 Million
Q2 2021 Aug 13, 2021	BUY	$15.46 - $24.5 $85,710 - $135,828	5,544 Added 4.1%	140,758 $2.81 Million
Q1 2021 May 17, 2021	BUY	$19.33 - $37.75 $2.61 Million - $5.1 Million	135,214 New	135,214 $3.12 Million

1.04M

30K

5.9K

Ticker ICPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,127,400
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...

Get notified when there are updates to the investment portfolio of Hennion & Walsh Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Hennion & Walsh Asset Management, Inc. with notifications on news.